Bert Gordijn

Definition of the problem: Cord blood banks have been and are still being set up in many modern states all over the world. Cord blood transplantation, however, gives rise to a specific set of ethical problems, that must be cleared up and analyzed before full responsibility can be assumed and the establishment of banks for frozen cord blood samples and the structural implementation of cord blood transplantation can be justified. The main ethical issues concerning cord blood stem cell transplantation can be divided into at least six groups of questions that are closely related. First, there are ethical issues concerning the status of the treatment. Must cord blood transplantation somehow still be considered an „investigational” treatment or can it be regarded as accepted therapy? Second, we must face the question of the ownership of the placental tissue. Third, there are questions regarding the fairness in the collection and distribution of cord blood. Fourth, there is the issue of informed consent. Fifth, there is the question of whether how new data from medical testing will be communicated to the parents or the donor. Finally, questions related to privacy and confidentiality need to be addressed. Conclusion: As it is likely in the years to come that the supply and demand for cord blood will grow, clinicians will increasingly need answers to these ethical questions. Only thoughtful analysis of the attendant ethical issues of the establishment of banks for frozen blood samples and the structural implementation of cord blood transplantation can mitigate potential problems

In genomic research the ideal standard of free, informed, prior, and explicit consent is believed to restrict important research studies. For certain types of genomic research other forms of consent are therefore proposed which are ethically justified by an appeal to the common good. This notion is often used in a general sense and this forms a weak basis for the use of weaker forms of consent. Here we examine how the notion of the common good can be related to individual health, health care, and genomic research and we use this analysis to propose more precise criteria to justify forms of consent which diverge from the ideal standard.

The volume contributes to the ongoing nanoethics debate in four topical areas. The first part tackles questions of what could be called ‘meta-nanoethics’. Its focus lies on basic concepts and the issue of what - if anything - is truly novel and special about the new field of nanoethics or its subject matter. The second part of this volume presents a selection of interesting perspectives on some of the opportunities and challenges of nanotechnology. Part three takes a more in depth look at one of the most pressing current concerns: how to deal with the risks and uncertainties surrounding nanotechnology in a responsible manner. In its fourth and final part the volume touches on issues of public debate and policy.

When we founded Studies in Ethics, Law and Technology we wondered if we might, like Icarus, be trying to fly too close to the sun. Had we set ourselves an impossible task in seeking to create a new community of interdisciplinary scholars under the umbrella of the words ethics, law and technology? Would expert scholars in biotechnologies, nanotechnologies, neurotechnologies, information technologies, weapons and security technologies, energy and fuel technologies, space based technologies, and/or new media and communication technologies all come together in one place? As we show in this editorial, the answer is yes.

In a lifelog, data from various sources are combined to form a record from which one can retrieve information about oneself and the environment in which one is situated. It could be considered similar to an automated biography. Lifelog technology is still at an early stage of development. However, the history of lifelogs so far shows a clear academic, corporate and governmental interest. Therefore, a thorough inquiry into the ethical aspects of lifelogs could prove beneficial to the responsible development of this field. This article maps the main ethically relevant challenges and opportunities associated with the further development of lifelog technologies as discussed in the scholarly literature. By identifying challenges and opportunities in the current debate, we were able to identify other challenges and opportunities left unmentioned. Some of these challenges are partly explained by a blind spot in the current debate. Whilst the current debate focuses mainly on lifelogs held by individuals, lifelogs held by governmental institutions and corporations pose idiosyncratic ethical concerns as well. We have provided a brief taxonomy of lifelog technology to show the variety in uses for lifelogs. In addition, we provided a general approach to alleviate the ethical challenges identified in the critical analysis

In this article, the question is discussed if and how Healthcare Ethics Committees (HECs) should be regulated. The paper consists of two parts. First, authors from eight EC member countries describe the status quo in their respective countries, and give reasons as to the form of regulation they consider most adequate. In the second part, the country reports are analysed. It is suggested that regulation of HECs should be central and weak. Central regulation is argued to be apt to improve HECs’ accountability, relevance and comparability. To facilitate biomedical citizenship and ethical reflection, regulation should at the same time be weak rather than strict. Independence of HECs to deliberate about ethical questions, and to give solicited and unsolicited advice, should be supported and only interfered with by way of exception. One exception is when circumstances become temporary adversarial to ethical deliberation in healthcare institutions. In view of European unification, steps should be taken to develop consistent policies for both Eastern and Western European countries

ABSTRACT In genomic research the ideal standard of free, informed, prior and explicit consent is sometimes difficult to apply. This has raised concern that important genomic research will be restricted. Different consent procedures have therefore been proposed. This paper explicitly examines the question how, in genomic research, the principles of solidarity and justice can be used to justify forms of diminished individual control over personal data and bio‐samples. After a discussion of the notions of solidarity and justice and how they can be related to health care and genomic research, we examine how and in which situations these notions can form a strong moral basis for demanding certain financial sacrifices. Then we examine when these principles can justify consent procedures which diverge from the ideal standard. Because much genomic research is not expected to lead to immediate (clinical) benefits we also discuss the question of whether we can be obliged to make any sacrifices for future (not yet existing) patients. We conclude with the formulation of a number of conditions that have to be met before autonomy sacrifices can be reasonably demanded in genomic research.

Definition of the Problem: The ethical debate on the cloning of human beings is by no means new. Its history goes back to the middle of the 1960s. However, the theoretical level of the contents of this debate still doesn't seem to have got past its initial stages.Arguments and conclusion: First, a short overview will be given of these 30 years of history of ethical debate, and some central concepts will be explained. Subsequently a critical analysis will be made of the arguments for and against the cloning of people which are used in this debate. The intention of this exposition is to stimulate further ethical discussion on the cloning of human beings